Stock Scorecard



Stock Summary for Jasper Therapeutics Inc (JSPR) - $2.33 as of 10/24/2025 5:34:22 PM EST

Total Score

11 out of 30

Safety Score

27 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for JSPR

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for JSPR

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for JSPR

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for JSPR

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for JSPR (27 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for JSPR

JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Jasper Therapeutics ( NASDAQ:JSPR ) 10/23/2025 12:55:00 PM
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - JSPR - Jasper Therapeutics ( NASDAQ:JSPR ) 10/23/2025 3:11:00 AM
JSPR Investors Should Contact Robbins LLP Regarding the Upcoming Lead Plaintiff Deadline in the Jasper Therapeutics, Inc. Class Action - Jasper Therapeutics ( NASDAQ:JSPR ) 10/23/2025 12:40:00 AM
ROSEN, A LEADING LAW FIRM, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - JSPR 10/22/2025 1:20:00 AM
JASPER CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Jasper Therapeutics Investors to Contact the Firm Regarding Class Action Lawsuit - Jasper Therapeutics ( NASDAQ:JSPR ) 10/21/2025 9:08:00 PM
ROSEN, A TOP-RANKED INVESTOR RIGHTS FIRM, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - JSPR 10/20/2025 1:10:00 AM
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - JSPR - Jasper Therapeutics ( NASDAQ:JSPR ) 10/20/2025 12:18:00 AM
ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - JSPR 10/19/2025 1:10:00 AM
DEADLINE ALERT for CYTK, NX, JSPR, and KBR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Cytokinetics ( NASDAQ:CYTK ) , Jasper Therapeutics ( NASDAQ:JSPR ) 10/17/2025 4:07:00 PM
DEADLINE ALERT for NX, JSPR, KBR, RICK: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions - Jasper Therapeutics ( NASDAQ:JSPR ) , KBR ( NYSE:KBR ) 10/17/2025 4:00:00 PM

Financial Details for JSPR

Company Overview

Ticker JSPR
Company Name Jasper Therapeutics Inc
Country USA
Description N/A
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 2.33
Price 4 Years Ago 78.50
Last Day Price Updated 10/24/2025 5:34:22 PM EST
Last Day Volume 328,579
Average Daily Volume 446,974
52-Week High 26.05
52-Week Low 2.21
Last Price to 52 Week Low 5.43%

Valuation Measures

Trailing PE N/A
Industry PE 22.95
Sector PE 41.12
5-Year Average PE -9.65
Free Cash Flow Ratio 1.65
Industry Free Cash Flow Ratio 14.54
Sector Free Cash Flow Ratio 31.25
Current Ratio Most Recent Quarter 2.10
Total Cash Per Share 1.41
Book Value Per Share Most Recent Quarter 1.45
Price to Book Ratio 2.88
Industry Price to Book Ratio 29.98
Sector Price to Book Ratio 32.29
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 31.95
Sector Price to Sales Ratio Twelve Trailing Months 16.43
Analyst Buy Ratings 3
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 27,924,000
Market Capitalization 65,062,920
Institutional Ownership 50.01%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -10.55%
Reported EPS 12 Trailing Months -6.05
Reported EPS Past Year -3.15
Reported EPS Prior Year -4.86
Net Income Twelve Trailing Months -90,922,000
Net Income Past Year -71,269,000
Net Income Prior Year -64,465,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 159.65%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 39,510,000
Total Cash Past Year 71,637,000
Total Cash Prior Year 86,887,000
Net Cash Position Most Recent Quarter 39,510,000
Net Cash Position Past Year 71,619,000
Long Term Debt Past Year 18,000
Long Term Debt Prior Year 18,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 61,674,000
Total Stockholder Equity Prior Year 78,440,000
Total Stockholder Equity Most Recent Quarter 23,501,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -73,858,000
Free Cash Flow Per Share Twelve Trailing Months -2.64
Free Cash Flow Past Year -63,154,000
Free Cash Flow Prior Year -52,334,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.03
MACD Signal -0.06
20-Day Bollinger Lower Band 0.83
20-Day Bollinger Middle Band 3.36
20-Day Bollinger Upper Band 5.89
Beta 2.80
RSI 49.74
50-Day SMA 7.52
150-Day SMA 13.30
200-Day SMA 17.09

System

Modified 10/23/2025 2:45:02 AM EST